[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE248598T1 - Inhibitoren der kainsäure-neurotoxizität sowie pyridothiazinderivate - Google Patents

Inhibitoren der kainsäure-neurotoxizität sowie pyridothiazinderivate

Info

Publication number
ATE248598T1
ATE248598T1 AT96938464T AT96938464T ATE248598T1 AT E248598 T1 ATE248598 T1 AT E248598T1 AT 96938464 T AT96938464 T AT 96938464T AT 96938464 T AT96938464 T AT 96938464T AT E248598 T1 ATE248598 T1 AT E248598T1
Authority
AT
Austria
Prior art keywords
formula
inhibitors
neuronotoxicity
kaine
pharmaceutically acceptable
Prior art date
Application number
AT96938464T
Other languages
English (en)
Inventor
Jun-Ichi Shishikura
Hiroshi Inami
Tomoyuki Yasunaga
Masaaki Hirano
Shuichi Sakamoto
Kazushige Ohno
Masamichi Okada
Shin-Ichi Tsukamoto
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Application granted granted Critical
Publication of ATE248598T1 publication Critical patent/ATE248598T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT96938464T 1995-11-15 1996-11-14 Inhibitoren der kainsäure-neurotoxizität sowie pyridothiazinderivate ATE248598T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP29685795 1995-11-15
PCT/JP1996/003339 WO1997017970A1 (fr) 1995-11-15 1996-11-14 Inhibiteurs de la neurotoxicite de l'acide kainique et derives de la pyridothiazine

Publications (1)

Publication Number Publication Date
ATE248598T1 true ATE248598T1 (de) 2003-09-15

Family

ID=17839067

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96938464T ATE248598T1 (de) 1995-11-15 1996-11-14 Inhibitoren der kainsäure-neurotoxizität sowie pyridothiazinderivate

Country Status (12)

Country Link
US (1) US6133258A (de)
EP (1) EP0878196B1 (de)
JP (1) JP3117725B2 (de)
KR (1) KR100444697B1 (de)
CN (1) CN1202109A (de)
AT (1) ATE248598T1 (de)
AU (1) AU713847B2 (de)
CA (1) CA2237911A1 (de)
DE (1) DE69629838T2 (de)
ES (1) ES2206604T3 (de)
TW (1) TW446708B (de)
WO (1) WO1997017970A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
EP1100504A2 (de) * 1998-07-02 2001-05-23 Eisai Co., Ltd. Pharmazeutische zubereitungen und verwendung zur behandlung demyelinisierender erkrankungen
AU3704400A (en) * 1999-03-04 2000-09-21 E.I. Du Pont De Nemours And Company Fused bicyclic oxazinone and thiazinone fungicides
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
PT1187612E (pt) * 1999-06-04 2005-05-31 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Utilizacao do riluzole para o tratamento da esclerose multipla
CA2479495A1 (en) 2002-03-29 2003-10-09 Yamanouchi Pharmaceutical Co., Ltd. Remedy for glioblastoma
AU2003295605A1 (en) * 2002-11-19 2004-06-15 Achillion Pharmaceuticals, Inc. Substituted aryl thioureas and releated compounds; inhibitors of viral replication
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
CN104672256B (zh) * 2013-11-29 2017-10-31 沈阳药科大学 4H‑吡啶并[3,2‑e][1,3]噻嗪‑4‑酮类衍生物及其应用
WO2016039936A2 (en) * 2014-09-09 2016-03-17 Ptc Therapeutics, Inc. Monocyclic substituted 2-pyridinone antibacterial compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3157647A (en) * 1960-10-31 1964-11-17 Olin Mathieson Process for producing nu-alkyl and nu-aralkyl thiadiazine compounds
US3288678A (en) * 1963-09-12 1966-11-29 Ciba Geigy Corp Diuretic compositions
GB1368948A (en) * 1970-11-11 1974-10-02 Manuf Prod Pharma Pyridine derivatives
FR2703051B1 (fr) * 1993-03-26 1995-04-28 Adir Nouvelles pyridothiadiazines, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
FR2722502B1 (fr) * 1994-07-12 1996-08-23 Adir Nouveau derive de benzothiadiazine, son procede depreparation et les compositions pharmaceutiques qui le contiennent

Also Published As

Publication number Publication date
US6133258A (en) 2000-10-17
TW446708B (en) 2001-07-21
EP0878196B1 (de) 2003-09-03
AU713847B2 (en) 1999-12-09
DE69629838D1 (de) 2003-10-09
DE69629838T2 (de) 2004-07-08
WO1997017970A1 (fr) 1997-05-22
EP0878196A4 (de) 2001-04-11
AU7587096A (en) 1997-06-05
KR100444697B1 (ko) 2005-01-13
ES2206604T3 (es) 2004-05-16
EP0878196A1 (de) 1998-11-18
JP3117725B2 (ja) 2000-12-18
KR19990067528A (ko) 1999-08-25
CN1202109A (zh) 1998-12-16
CA2237911A1 (en) 1997-05-22

Similar Documents

Publication Publication Date Title
LU91210I2 (fr) Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
CA2311742A1 (en) 6-amino-9-benzyl-8-hydroxypurine derivatives
ATE211734T1 (de) Stickstoff enthaltende hydrocyclische verbindungen
ATE170840T1 (de) Hydroxamsäure derivate als collagenase inhibitore
ATE223378T1 (de) Prolineamid-derivate
ATE156116T1 (de) Auf aromatischen sulfonamiden basierende hydroxamsäurederivate
DE69328856D1 (de) Hypoglykämische Dihydrochalconderivate
DE69820248D1 (de) Pyrrolidin-derivate die eine phospholipase-a2-hemmende wirkung haben
AU689304B2 (en) Quinazoline derivative
EP1176141A4 (de) HETEROCYCLISCHE VERBINDUNGEN DIE EINEN DEN NIKOTIN-ACETYLCHOLIN -g(a)4-g(b)2-REZEPTOR AKTIVIERENDEN EFFEKT BESITZEN
ATE248598T1 (de) Inhibitoren der kainsäure-neurotoxizität sowie pyridothiazinderivate
DE69725585D1 (de) Phenylalkylcarbonsäure-derivate
ATE182331T1 (de) Oxazolidone derivative als monoamine- oxidaseinhibitoren
DE69329084D1 (de) Benzoxazepin-Derivate als Cholinesterase-Inhibitoren
DE69600231D1 (de) N-Arylalkylphenylacetamidderivate
EP0982029A4 (de) Vorbeugende /heilmittel fuer arteriosklerose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties